An expanded analysis that profiles the response of BRAFi-resistant melanoma cells to mitotic inhibitors is necessary to fully elucidate the molecular features predictive of response to the combination of BRAF inhibitors and mitotic inhibitors. Here, BRAF is linked to melanoma.